Precision Medicine in Oncology

Exploring the Use of Liquid Biopsy–Based Biosensors for MRD Assessment in NSCLC

November 29th 2021, 1:00pm

Article

In a recent study, researchers detailed the use of various biosensors for minimal residual disease (MRD) detection in non–small cell lung cancer (NSCLC).

Review Finds Room for Improvement in MRD Detection Via Liquid Biopsy for Solid Tumor Cancers

November 27th 2021, 4:30pm

Article

A recent review outlined advances and challenges in utilizing liquid biopsy to detect measures such as circulating tumor DNA in patients with solid tumors.

Panel Offers Consensus Recommendations for MRD Assessment in CLL

November 24th 2021, 2:16pm

Article

The recommendations come at a time when treatments for chronic lymphocytic leukemia (CLL), such as venetoclax, are making deep remissions and undetectable minimal residual disease (MRD) after a fixed duration of treatment feasible goals.

Palmetto GBA’s MolDX Announces Coverage of MRD Testing

November 20th 2021, 10:43pm

Article

The decision will provide Medicare coverage tests for minimal residual disease (MRD) starting December 26, 2021.

Dr Funmi Olopade: Breast Cancer Screening Is Not One Size Fits All

November 20th 2021, 1:15pm

Video

Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how different populations are at different risk for breast cancer and the importance of informed screening.

Can Conditionally Reprogramming Cells Expand the Scope of Precision Oncology?

November 19th 2021, 5:00pm

Article

The approach works by transforming the condition of normal and tumor cells into a highly proliferative “reprogrammed stem-like” condition that still has the original karyotypes.

Case Study Indicates Drug Sensitivity Testing-Guided Treatment May Improve PFS in SRMS

November 13th 2021, 5:15pm

Article

The drug sensitivity test-guided treatment was associated with significant improvements in the patient’s condition after 8 weeks.

New Research Underscores Need for More Diversity in Precision Oncology Studies

November 11th 2021, 5:00pm

Article

Across all studies included, observed-to-expected ratios showed that White and Asian patients were overrepresented while Black patients, Hispanic patients, and American Indian/Alaskan Native patients were underrepresented.

Tumor In Situ Fluid DNA Can Reveal Recurrence Risk in Glioma

November 4th 2021, 2:45pm

Article

A study suggests tumor in situ fluid is a better choice when trying to extract tumor DNA in patients with glioma who underwent surgery.

Study: Host Immune Classifier Test Predicts ICI Response in Advanced NSCLC

November 2nd 2021, 1:45pm

Article

Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification.